This document describes the operating model for the UK Therapeutics Advisory Panel for Pandemic (TAPP). The TAPP concept is based on the operating model adopted by the UK COVID-19 Therapeutics Advisory Panel (UK-CTAP) (Chinnery et al., 2021) .The model evolved over the course of the COVID-19 pandemic. The TAPP model embraces lessons learned in the process of delivering and evaluating the effectiveness of UK-CTAP. It is an agile working model that is optimised for speed of decision making by providing unbiased due diligence, transparent and independent scientific evaluation of therapeutics. UK-CTAP was widely praised as a highly effective trial candidate prioritisation system The TAPP concept addresses the necessary assets, systems and processes needed to effectively triage large numbers of repurposed and novel drugs into a platform trials system. It is a cooperative approach that ensures key partners from across the scientific research and healthcare sectors are linked and focused on delivering effective treatments that reach patients faster and safely. This operating model will address only the set up and operation of a TAPP and will not address whether the TAPP is the optimum tool for this function. This operating manual may be used in conjunction with a set of standard operating procedures collated as part of UK-CTAP legacy.

{"references": ["Chinnery, P.F., Bonnet, M., Cave, A., Hofer, M.P., Lamb, A., McConkey, G.A., Medcalf, N., Smith, S.P., Tsakok, T., Watson, R., Webster, S.,& You T (2021). Choosing drugs for UK COVID-19 treatment trials. Nature Reviews Drug Discovery. http://doi: 10.1038/d41573-021-00203-7.", "https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/992762/100_Days_Mission_to_respond_to_future_pandemic_threats__3_.pdf"]}